Altimmune Inc

-$0.06 (-0.8%)
Closing price May 24, 2024

ALT Chart and Intraday Price

ALT Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 649.58M USD
Shares Outstanding 53,729,000
Altimmune Inc is a biopharmaceutical company based in Gaithersburg, Maryland, focusing on innovative treatments for obesity and liver diseases. Its leading product, pemvidutide, is a promising obesity and non-alcoholic steatohepatitis treatment currently in Phase 2 trials. Additionally, Altimmune is developing HepTcell, aimed at treating chronic hepatitis B virus infections, also in Phase 2 trials. Founded in 1997 and originally named Vaxin Inc., the company rebranded to Altimmune Inc in 2015, continuing its mission to address critical unmet medical needs.

ALT Articles

Thursday’s additional top analyst upgrades and downgrades were on Ally Financial, Altimmune, Capital One Financial, GoodRx, Leslie’s, PagSeguro Digital, Regions Financial, Sirius XM, StoneCo,...
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Wednesday's top analyst upgrades and downgrades included Alphabet, Canopy Growth, Cinemark, Dick's Sporting Goods, Facebook, IMAX, Microsoft, and SBA Communications.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Thursday's top analyst upgrades and downgrades included Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter and Under Armour.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing agreement the vaccine candidate.
Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
24/7 Wall St. has tracked some stocks that either are defensive in general or are defying Monday's big drop because they have some aspect of their business that might be immune to daily scares or...
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.